March 25, 2020 / 8:05 PM / 7 days ago

BRIEF-Agios Provides Update On 2016 Collaboration Agreement With Celgene

March 25 (Reuters) - Agios Pharmaceuticals Inc:

* AGIOS PROVIDES UPDATE ON 2016 COLLABORATION AGREEMENT WITH CELGENE, A WHOLLY OWNED SUBSIDIARY OF BRISTOL MYERS SQUIBB

* AGIOS PHARMACEUTICALS INC - CELGENE DECLINES TO EXERCISE OPT-IN RIGHT FOR MAT2A INHIBITOR AG-270

* AGIOS PHARMACEUTICALS - RESEARCH TERM OF METABOLIC IMMUNO-ONCOLOGY COLLABORATION TO CONCLUDE AT END OF INITIAL FOUR-YEAR PERIOD IN MAY 2020

* AGIOS PHARMACEUTICALS - AG-270 PHASE 1 COMBINATION EXPANSION TRIALS ONGOING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below